Abstract
Helicobacter pylori (H. pylori), a prevalent human-specific pathogen, plays
a key role in the development of peptic ulcer disease, gastric carcinoma, and gastric
mucosa associated lymphoid tissue lymphoma. Once infected, those bacteria reside
below the gastric mucosa adherent to the gastric epithelium, and entry of drugs to this
target site is very difficult. The bacteria can also acquire resistance to commonly used
antimicrobial drugs. Thus, an effective antimicrobial concentration cannot be achieved
in the gastric mucous layer or on the epithelial cell surfaces where H. pylori exist and
caused inefficient treatment. Such challenges have encouraged researchers into
developing some therapies based on nanotechnology.
Related Journals
Drug Delivery Letters
Recent Advances in Anti-Infective Drug Discovery
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Bioactive Compounds
Current Drug Delivery
Current Drug Safety
Drug Metabolism and Bioanalysis Letters
Recent Advances in Drug Delivery and Formulation
Reviews on Recent Clinical Trials
Current Drug Metabolism
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms